Primary cutaneous mucormycosis of the abdomen at the site of repeated insulin injections.
Abdomen
/ pathology
Aged
Anti-Bacterial Agents
/ therapeutic use
Antifungal Agents
/ therapeutic use
Dermatomycoses
/ microbiology
Diabetes Mellitus, Type 2
/ drug therapy
Female
Humans
Immunocompromised Host
Injection Site Reaction
/ microbiology
Injections, Subcutaneous
/ adverse effects
Insulin
/ adverse effects
Lung Neoplasms
/ complications
Mucormycosis
/ etiology
Necrosis
Nitriles
/ therapeutic use
Pyridines
/ therapeutic use
Triazoles
/ therapeutic use
Vancomycin
/ therapeutic use
dermatology
diabetes
infections
infectious diseases
Journal
BMJ case reports
ISSN: 1757-790X
Titre abrégé: BMJ Case Rep
Pays: England
ID NLM: 101526291
Informations de publication
Date de publication:
10 Feb 2020
10 Feb 2020
Historique:
entrez:
13
2
2020
pubmed:
13
2
2020
medline:
21
10
2020
Statut:
epublish
Résumé
A 71-year-old woman with metastatic squamous cell carcinoma of the lung and insulin-dependent type 2 diabetes mellitus presented with a necrotic lesion on her lower abdomen. Further history revealed that this was the site of repeat insulin injections with reuse of the same needles. On investigation, biopsy of the site was positive for broad, aseptate, right-angle branching fungal hyphae consistent with mucormycosis. Studies have shown that insulin needle reuse is a common practice among diabetics for several reasons, including cost and convenience. While the current American Diabetes Association guidelines suggest that this is an acceptable practice among the general population of diabetics, they advise against it in patients who are actively ill or immunocompromised. Discussion about insulin needle reuse should be of utmost importance among providers and their diabetic patients, especially for patients who are immunocompromised.
Identifiants
pubmed: 32047088
pii: 13/2/e233284
doi: 10.1136/bcr-2019-233284
pmc: PMC7035857
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Antifungal Agents
0
Insulin
0
Nitriles
0
Pyridines
0
Triazoles
0
isavuconazole
60UTO373KE
Vancomycin
6Q205EH1VU
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
J Drugs Dermatol. 2010 Nov;9(11):1439-42
pubmed: 21061769
J Am Acad Dermatol. 2011 May;64(5):e79-81
pubmed: 21496690
J Am Acad Dermatol. 1990 May;22(5 Pt 2):956-9
pubmed: 2335589
Acta Clin Belg. 2017 Oct;72(5):352-356
pubmed: 28019140
Clin Microbiol Infect. 2014 Jun;20 Suppl 6:74-81
pubmed: 24279587
Clin Infect Dis. 2005 Sep 1;41(5):634-53
pubmed: 16080086
Int J Nurs Stud. 2016 Aug;60:121-32
pubmed: 27297374
Clin Dermatol. 2012 Nov-Dec;30(6):628-32
pubmed: 23068150
Nurs Res. 1987 Nov-Dec;36(6):350-2
pubmed: 3313291
Eur J Clin Microbiol Infect Dis. 2006 Apr;25(4):215-29
pubmed: 16568297
Clin Infect Dis. 2012 Feb;54 Suppl 1:S23-34
pubmed: 22247442
Diabetes Care. 2004 Jan;27 Suppl 1:S106-9
pubmed: 14693942